AVITA Medical (RCEL) Stock Price

AVITA Medical Price

NASDAQ·CLOSED
4.49USD-0.24 (-5.31 %)
Market closed

Over the last 5 years AVITA Medical grew revenue by 35.1% annually, reaching 64.25 M USD. For AVITA Medical, the net margin of -96.3% is down versus -90.9% a few years ago. The consensus 12-month price target for AVITA Medical is 5.61 USD, about 24.8% above where the stock trades today. Of 12 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 37% above its 52-week low.

AVITA Medical stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of AVITA Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how AVITA Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing AVITA Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

AVITA Medical Stock Price History
DateAVITA Medical Price
8/5/20264.49 USD
8/4/20264.74 USD
8/3/20264.62 USD
7/31/20264.40 USD
7/30/20264.49 USD
7/29/20264.43 USD
7/27/20264.81 USD
7/23/20264.61 USD
7/22/20264.94 USD
7/21/20265.09 USD
7/20/20265.14 USD
7/17/20265.10 USD
7/16/20264.98 USD
7/15/20264.73 USD
7/14/20264.02 USD
7/13/20263.91 USD
7/10/20264.06 USD
7/9/20264.41 USD
7/8/20264.70 USD
7/7/20265.00 USD
7/6/20264.92 USD
7/2/20265.06 USD
7/1/20264.67 USD
6/30/20264.13 USD
6/29/20264.25 USD
6/26/20263.97 USD
6/25/20263.92 USD
6/24/20263.95 USD
6/23/20263.92 USD
6/22/20264.02 USD
6/18/20264.01 USD
6/17/20263.94 USD
6/16/20263.92 USD
6/15/20263.93 USD
6/12/20263.91 USD
6/11/20263.97 USD
6/10/20264.12 USD
6/9/20264.12 USD
6/8/20264.16 USD
6/5/20264.18 USD
6/4/20264.36 USD
6/3/20264.16 USD
6/2/20264.19 USD
6/1/20264.38 USD
5/29/20264.33 USD
5/28/20264.39 USD
5/27/20264.20 USD
5/26/20264.25 USD
5/22/20264.58 USD
5/21/20264.48 USD
5/20/20264.32 USD
5/19/20264.20 USD
5/18/20264.19 USD
5/15/20264.56 USD
5/14/20264.36 USD
5/13/20264.26 USD
5/12/20264.38 USD
5/11/20264.37 USD
5/8/20264.11 USD
5/7/20264.18 USD
5/6/20264.42 USD
5/5/20264.24 USD
5/4/20264.28 USD
4/22/20264.67 USD
4/21/20264.77 USD
4/20/20265.00 USD
4/17/20265.14 USD
4/16/20264.99 USD
4/15/20265.16 USD
4/14/20265.60 USD
4/13/20264.91 USD
4/10/20265.01 USD
4/9/20264.54 USD
4/8/20264.10 USD
4/7/20263.87 USD
4/6/20263.90 USD
4/2/20263.71 USD
4/1/20263.77 USD
3/31/20263.70 USD
3/30/20263.63 USD
3/27/20263.82 USD
3/26/20263.86 USD
3/25/20263.99 USD
3/24/20263.84 USD
3/23/20263.95 USD
3/20/20263.95 USD
3/19/20264.03 USD
3/18/20264.19 USD
3/17/20264.47 USD
3/16/20264.62 USD
3/13/20264.40 USD
3/12/20264.58 USD
3/11/20264.80 USD
3/10/20264.90 USD
3/9/20264.96 USD
3/6/20264.75 USD
3/5/20264.78 USD
3/4/20264.96 USD
3/3/20264.81 USD
3/2/20265.27 USD
2/27/20265.03 USD
2/26/20265.11 USD
2/25/20265.00 USD
2/24/20265.39 USD
2/23/20264.85 USD
2/20/20264.79 USD
2/19/20264.38 USD
2/18/20264.31 USD
2/17/20264.31 USD
2/13/20264.16 USD
2/12/20263.72 USD
2/11/20263.84 USD
2/10/20264.00 USD
2/9/20264.05 USD
2/6/20263.90 USD
2/5/20263.93 USD
2/4/20264.08 USD
2/3/20264.30 USD
2/2/20264.24 USD
1/30/20264.41 USD
1/29/20264.36 USD
1/28/20264.44 USD
1/27/20264.57 USD
1/26/20264.53 USD
1/23/20264.44 USD
1/22/20264.13 USD
1/21/20263.89 USD
1/20/20263.77 USD
1/16/20263.90 USD
1/15/20263.46 USD
1/14/20263.52 USD
1/13/20263.30 USD
1/12/20263.42 USD
1/9/20263.40 USD
1/8/20263.28 USD
1/7/20263.29 USD
1/6/20263.42 USD
1/5/20263.47 USD
1/2/20263.47 USD
12/31/20253.45 USD
12/30/20253.45 USD
12/29/20253.44 USD
12/26/20253.44 USD
12/24/20253.52 USD
12/23/20253.44 USD
12/22/20253.43 USD
12/19/20253.46 USD
12/18/20253.36 USD
12/17/20253.27 USD
12/16/20253.33 USD
12/15/20253.40 USD
12/12/20253.46 USD
12/11/20253.53 USD
12/10/20253.50 USD
12/9/20253.53 USD
12/8/20253.45 USD
12/5/20253.50 USD
12/4/20253.55 USD
12/3/20253.51 USD
12/2/20253.60 USD
12/1/20253.59 USD
11/28/20253.70 USD
11/26/20253.91 USD
11/25/20253.75 USD
11/24/20253.75 USD
11/21/20253.79 USD
11/20/20253.84 USD
11/19/20253.95 USD
11/18/20253.95 USD
11/17/20253.86 USD
11/14/20253.75 USD
11/13/20253.74 USD
11/12/20253.78 USD
11/11/20253.96 USD
11/10/20253.97 USD
11/7/20253.77 USD
11/6/20253.40 USD
11/5/20253.50 USD
11/4/20253.62 USD
11/3/20253.78 USD
10/31/20253.87 USD
10/30/20253.67 USD
10/29/20253.69 USD
10/28/20253.66 USD
10/27/20253.79 USD
10/24/20253.97 USD
10/23/20254.02 USD
10/22/20253.96 USD
10/21/20254.12 USD
10/20/20254.01 USD
10/17/20253.99 USD
10/16/20255.38 USD
10/15/20255.33 USD
10/14/20255.27 USD
10/13/20255.23 USD
10/10/20255.14 USD
10/9/20255.53 USD
10/8/20255.51 USD
10/7/20255.47 USD
10/6/20255.52 USD
10/3/20255.54 USD
10/2/20255.47 USD
10/1/20255.25 USD
9/30/20255.11 USD
9/29/20255.37 USD
9/26/20255.20 USD
9/25/20255.33 USD
9/24/20255.25 USD
9/23/20255.45 USD
9/22/20255.92 USD
9/19/20255.47 USD
9/18/20255.54 USD
9/17/20255.84 USD
9/16/20256.25 USD
9/15/20256.76 USD
9/12/20254.56 USD
9/11/20254.38 USD
9/10/20254.17 USD
9/9/20254.19 USD
9/8/20254.21 USD
9/5/20254.26 USD
9/4/20254.29 USD
9/3/20254.29 USD
9/2/20254.29 USD
8/29/20254.34 USD
8/28/20254.38 USD
8/27/20254.53 USD
8/26/20254.56 USD
8/25/20254.65 USD
8/22/20254.88 USD
8/21/20254.75 USD
8/20/20254.69 USD
8/19/20254.87 USD
8/18/20255.55 USD
8/15/20255.63 USD
8/14/20255.80 USD
8/13/20255.76 USD
8/12/20255.52 USD
8/11/20254.81 USD
8/8/20254.25 USD
8/7/20255.38 USD
Access this data via the Eulerpool API
Get Free API Key

AVITA Medical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
34.42 M USD
-27.13 M USD
-26.67 M USD
Jan 1, 2023
50.14 M USD
-42.35 M USD
-35.38 M USD
Jan 1, 2024
64.25 M USD
-56.00 M USD
-61.85 M USD
Jan 1, 2025 (e)
71.49 M USD
-52.92 M USD
-54.84 M USD
Jan 1, 2026 (e)
82.77 M USD
-61.26 M USD
-32.01 M USD
Jan 1, 2027 (e)
100.05 M USD
-74.05 M USD
-16.51 M USD
Jan 1, 2028 (e)
122.68 M USD
-90.80 M USD
-1.54 M USD
Jan 1, 2029 (e)
411.37 M USD
-304.47 M USD
84.15 M USD

AVITA Medical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 9:52 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2019202020212022202320242025e2026e2027e2028e2029e2030e2031e
14.0029.0013.0034.0050.0064.0071.0082.00100.00122.00411.00497.00410.00
–107.14-55.17161.5447.0628.0010.9415.4921.9522.00236.8920.92-17.51
78.5779.3192.3182.3584.0085.9485.9485.9485.9485.9485.9485.9485.94
11.0023.0012.0028.0042.0055.0061.0270.4785.94104.84353.20427.11352.34
-42.00-26.00-14.00-27.00-42.00-55.00-52.00-61.00-74.00-90.00-304.00-368.00–
-300.00-89.66-107.69-79.41-84.00-85.94-73.24-74.39-74.00-73.77-73.97-74.04–
-42.00-26.00-14.00-26.00-35.00-61.00-54.00-32.00-16.00-1.0084.00110.00148.00
–-38.10-46.1585.7134.6274.29-11.48-40.74-50.00-93.75-8,500.0030.9534.55
20.2922.6724.9225.0025.3325.8825.8825.8825.8825.8825.8825.8825.88
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales AVITA Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue AVITA Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare AVITA Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares AVITA Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against AVITA Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

AVITA Medical stock margins

The AVITA Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AVITA Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AVITA Medical.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
80.43 %
-90.01 %
-90.93 %
Jan 1, 2021
86.67 %
-102.73 %
-103.37 %
Jan 1, 2022
83.56 %
-78.82 %
-77.48 %
Jan 1, 2023
84.93 %
-84.45 %
-70.56 %
Jan 1, 2024
86.60 %
-87.16 %
-96.26 %
Jan 1, 2025 (e)
86.60 %
-74.01 %
-76.71 %
Jan 1, 2026 (e)
86.60 %
-74.01 %
-38.67 %
Jan 1, 2027 (e)
86.60 %
-74.01 %
-16.50 %

AVITA Medical Stock Revenue, EBIT, Earnings per Share

The AVITA Medical earnings per share therefore indicates how much revenue AVITA Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
1.29 USD
-1.16 USD
-1.17 USD
Jan 1, 2021
0.56 USD
-0.58 USD
-0.58 USD
Jan 1, 2022
1.38 USD
-1.09 USD
-1.07 USD
Jan 1, 2023
1.98 USD
-1.67 USD
-1.40 USD
Jan 1, 2024
2.48 USD
-2.16 USD
-2.39 USD
Jan 1, 2025 (e)
2.34 USD
-2.04 USD
-1.80 USD
Jan 1, 2026 (e)
2.71 USD
-2.37 USD
-1.05 USD
Jan 1, 2027 (e)
3.28 USD
-2.86 USD
-0.54 USD

AVITA Medical business model & stock analysis

AVITA Medical Inc is a company in the field of regenerative medicine that focuses on the development and marketing of innovative therapy products for the treatment of burns, chronic wounds, and skin defects. The company was founded in 1998 and is headquartered in Valencia, California. AVITA Medical Inc began with research in the field of regenerative medicine at the University of Western Australia, where the company developed its patented technology known as ReNovaCell. This technology allows for the extraction and cultivation of cells from a small area of skin to create a solution that contains the patient's own skin tissue on a large scale. AVITA Medical Inc's business model is based on the development and marketing of regenerative therapy products based on ReNovaCell technology. The company focuses on commercializing products that enable fast, safe, and effective treatment of burns, chronic wounds, and skin defects. AVITA Medical Inc operates in two main segments: regenerative medicine and aesthetic medicine. In regenerative medicine, the company offers a wide range of products based on ReNovaCell technology, including ReCell, a unique autologous cell therapy for rapid burn treatment, Kelo-Cote, a silicone gel formulation for scar treatment, and therapy-complementary wound treatments. In aesthetic medicine, the company distributes a variety of products under the brand RestoreSkin, which focuses on improving skin health and aesthetic appearance, including pore refinement, pigment reduction, and wrinkle reduction. AVITA Medical Inc has established itself as a leading provider of regenerative therapy products. The company has a strong presence both in the US and internationally and is actively advocating for the advancement of regenerative medicine. By developing innovative products that enable fast and effective treatment of skin defects, AVITA Medical Inc will continue to be a key player in regenerative medicine in the future.

AVITA Medical SWOT Analysis

Strengths

Advanced Technology: AVITA Medical Inc utilizes cutting-edge medical technology in their products and services, providing them with a competitive advantage in the market.

Strong Research and Development: The company invests heavily in R&D, allowing them to continuously innovate and develop new, effective solutions for the medical industry.

Established Market Presence: AVITA Medical Inc has built a solid reputation and established relationships with key stakeholders, including healthcare professionals and institutions.

Strong Financial Position: The company boasts a healthy financial standing, enabling them to fund their operations and pursue growth opportunities.

Weaknesses

Limited Product Portfolio: AVITA Medical Inc currently offers a limited range of products, which may limit their market reach and revenue potential.

Dependence on Regulatory Approvals: The company's success heavily relies on obtaining necessary approvals from regulatory authorities, which can delay product launches and impact profitability.

Relatively Small Customer Base: AVITA Medical Inc primarily caters to a niche market, which may result in limited customer base and slower market expansion.

Opportunities

Growing Demand for Regenerative Medicine: The increasing focus on regenerative medicine presents an opportunity for AVITA Medical Inc to expand their product offerings and capture a larger market share.

Expansion into New Geographical Markets: The company can explore untapped international markets to diversify their customer base and drive revenue growth.

Strategic Partnerships and Collaborations: AVITA Medical Inc can leverage strategic partnerships and collaborations with other industry players to enhance their technological capabilities and market presence.

Threats

Intense Competition: The medical industry is highly competitive, and AVITA Medical Inc faces competition from established players as well as emerging startups.

Evolving Regulatory Landscape: Changes in regulations and compliance requirements can impact AVITA Medical Inc's operations and product development processes.

Technological Advancements: Rapid technological advancements may render AVITA Medical Inc's existing products obsolete or less relevant, requiring continuous innovation to stay competitive.

AVITA Medical Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

AVITA Medical Employees
Details
Date
AVITA Medical Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

AVITA Medical Segments

AVITA Medical Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Japan
United Kingdom
Australia
European Union
Details
Date
United States
Japan
United Kingdom
Australia
European Union
Jan 1, 2020
13.80 M USD
0.00 USD
171,000.00 USD
292,000.00 USD
0.00 USD
Jan 1, 2021
28.96 M USD
0.00 USD
70,000.00 USD
207,000.00 USD
0.00 USD
Jan 1, 2022
33.26 M USD
729,000.00 USD
160,000.00 USD
275,000.00 USD
0.00 USD
Jan 1, 2024
62.16 M USD
1.43 M USD
196,000.00 USD
312,000.00 USD
155,000.00 USD
Jan 1, 2025
68.79 M USD
2.09 M USD
486,000.00 USD
200,000.00 USD
49,000.00 USD

AVITA Medical Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

AVITA Medical historical P/E ratio, EBIT multiple, and P/S ratio

AVITA Medical annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

AVITA Medical shares outstanding

The number of shares of AVITA Medical was 25.88 M in 2025. This indicates how many shares AVITA Medical is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
22.67 M Stocks
Jan 1, 2021
24.92 M Stocks
Jan 1, 2022
25.00 M Stocks
Jan 1, 2023
25.33 M Stocks
Jan 1, 2024
25.88 M Stocks
Jan 1, 2025 (e)
25.88 M Stocks
Jan 1, 2026 (e)
25.88 M Stocks
Jan 1, 2027 (e)
25.88 M Stocks

AVITA Medical stock splits

In AVITA Medical's history, there have been no stock splits.

Current AVITA Medical forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
75.00 % (9)
Hold
25.00 % (3)
Sell
0.00 % (0)
12M Price Target
5.61
Last Price
4.49
Currency
USD
12M Return Potential
24.81 %
LTM Return
0 %

AVITA Medical Analyst Rating Actions

DateFirmActionRatingReliability
5/15/2026
Lake Street
Lake Street
UpgradeHoldBuy–
4/9/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
4/8/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
2/17/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
1/26/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
1/16/2026
Lake Street
Lake Street
MaintainedHold–
1/15/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
11/20/2025
BTIG
BTIG
UpgradeSellNeutral–
11/7/2025
D. Boral Capital
D. Boral Capital
MaintainedBuy–
10/17/2025
Lake Street
Lake Street
DowngradeBuyHold–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

AVITA Medical Earnings Calls

2025

AVITA Medical Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/2026-0.29USD-20.57 MUSD-2026 Q2
5/14/2026-0.29USD-18.54 MUSD-2026 Q1
2/12/2026-0.37USD-18.19 MUSD-2025 Q4
11/7/2024-0.45USD-19.81 MUSD-2024 Q3
11/10/2022-0.31USD-8.98 MUSD-2023 Q1
8/27/2020-0.25USD-6.74 MUSD-2020 Q4

EESG©

Eulerpool ESG Scorecard© for the AVITA Medical stock

45/100
46
Environment
65
Social
23
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees50.2
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

AVITA Medical shareholder structure

% Name
5.69926%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.75686%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.02802%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
1.73429%
State Street Investment Management (US)
State Street Investment Management (US)
1.34404%
UBS Financial Services, Inc.
UBS Financial Services, Inc.
1.27753%
Opaleye Management Inc.
Opaleye Management Inc.
...

AVITA Medical Beneficial Ownership Filings (SEC 13D/G)

Free Float
96.2%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
7.10%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
5.45%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
4.73%
The Vanguard Group
The Vanguard Group
SEC ↗
4.30%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
2.70%
Redmile Group, LLC
Redmile Group, LLC
SEC ↗
2.70%
Jeremy C. Green
Jeremy C. Green
SEC ↗

AVITA Medical Executives and Management Board

11 members · avg. age 66 · 36 % women

JC

Mr. James Corbett (66)

President, Chief Executive Officer, Executive Director · since 2021

3.24 M USD

Management

DO

Mr. David O'Toole (66)

Chief Financial Officer

1.78 M USD
NK

Ms. Nicole Kelsey (58)

Chief Legal and Compliance Officer, Corporate Secretary

1.29 M USD

Board of Directors

LP

Mr. Lou Panaccio (67)

Independent Non-Executive Chairman of the board · since 2014

235,252.00 USD
JR

Ms. Jan Reed (65)

Independent Non-Executive Director

209,474.00 USD
CV

Mr. Cary Vance (59)

Independent Non-Executive Director

207,752.00 USD
RM

Mr. Robert Mcnamara (68)

Independent Non-Executive Director

203,141.00 USD
JC

Mr. Jeremy Cook (75)

Independent Non-Executive Director

196,029.00 USD
PC

Prof. Suzanne Crowe (74)

Independent Non-Executive Director

196,029.00 USD

AVITA Medical Supply Chain

AVITA Medical Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
M3
Customer·Health Care Technology·JP
-0.54
0.78
0.57
0.86
0.94
0.57
#NameTrend
1
Premier A
Customer·Health Care Providers & Services·US
-0.23
-0.06
-0.34
0.66
0.05
-0.57
2
BlackRock
Supplier·Customer·Capital Markets·US
0.28
0.85
0.86
0.96
0.80
-0.29

Frequently asked questions about AVITA Medical

AVITA Medical Inc is a regenerative medicine company that specializes in developing and commercializing innovative treatments for a variety of skin defects and conditions. Their business model revolves around leveraging their proprietary technology, known as the RECELL® System, which enables the rapid and efficient regeneration of skin cells. AVITA Medical aims to transform the lives of patients by providing advanced solutions for burns, chronic wounds, and aesthetic indications. Through collaborations, research, and a patient-centered approach, AVITA Medical Inc strives to improve outcomes and quality of life for individuals in need of effective skin restoration.

AVITA Medical Inc is primarily active in the healthcare and biotechnology industries. With a focus on regenerative medicine solutions, AVITA Medical specializes in developing and commercializing innovative treatments for wounds, burns, and other skin-related conditions. Through its proprietary technology called the RECELL® System, the company aims to revolutionize the way healthcare professionals offer personalized skin regeneration solutions. AVITA Medical Inc's commitment to advancing patient care within the healthcare and biotech sectors has positioned it as a leader in the field, with its products offering promising benefits and potential advancements in wound healing and skin restoration.

The main competitors of AVITA Medical Inc in the market include companies such as Acelity (formerly known as KCI), Molnlycke Health Care, Smith & Nephew, and Dermatix.

AVITA Medical Inc. is a leading regenerative medicine company that specializes in the development and commercialization of innovative therapies for a range of skin conditions. Founded in 2002, AVITA Medical has grown into a globally recognized and respected company in the field. It is dedicated to utilizing its proprietary technology platform, the RECELL® System, to provide innovative and transformative solutions for patients with burns, chronic wounds, and aesthetic conditions. With a strong commitment to research and development, AVITA Medical continues to expand its product portfolio and improve patients' lives worldwide through its cutting-edge regenerative medicine treatments.

AVITA Medical Inc has achieved significant milestones in its journey. One notable accomplishment includes the FDA approval of its flagship product, RECELL® System, in September 2018. This innovative regenerative medicine device is used for the treatment of acute thermal burns in patients. Additionally, AVITA Medical Inc successfully established partnerships with leading medical centers and institutions globally, facilitating the adoption and utilization of the RECELL System. The company has also significantly expanded its global presence by securing market approvals in various countries. AVITA Medical Inc continues to make advancements in regenerative medicine, revolutionizing burn treatment and positively impacting patients' lives.

AVITA Medical Inc primarily operates in the United States, Europe, and Australia.

AVITA Medical Inc represents a values-driven corporate philosophy focused on transforming lives through innovative medical solutions. The company prioritizes patient-centric healthcare and aims to deliver cutting-edge regenerative products and technologies. AVITA Medical Inc is dedicated to providing advancements in the field of regenerative medicine, particularly in the treatment of acute and chronic wounds. By combining science, medical expertise, and compassion, AVITA Medical Inc strives to improve patient outcomes and enhance quality of life. As a leader in regenerative medicine, AVITA Medical Inc remains committed to sustainability, ethical practices, and driving meaningful change in the healthcare industry.

Analysts currently set an average price target of 6.32 USD for the AVITA Medical stock (median: 5.61 USD), implying +40.7 % versus the latest price. The consensus is based on 12 analyst ratings.

AVITA Medical Analyst Price Targets 2026

12 analysts currently rate the AVITA Medical stock: 9 recommend buying, 3 holding and 0 selling. For 2026, analysts expect AVITA Medical to generate revenue of 82.77 M USD and earnings per share of -1.24 USD.

AVITA Medical Analyst Price Targets 2026

Converted at the current exchange rate, the AVITA Medical share trades at 3.90 EUR (4.49 USD).

The AVITA Medical share (RCEL) is listed on 2 stock exchanges, including: NASDAQ (RCEL), Frankfurt (51KA.F).

AVITA Medical Inc is a leading company in the field of regenerative medicine, offering a wide range of products and services. The company's business model is based on three main divisions: the development and marketing of innovative and effective regenerative medicine products, the provision of wound care services, and the distribution of products and devices for medical applications. The first division of AVITA Medical's business model is the development and marketing of regenerative medicine products. The company specializes in the production of dermographs used to treat patients with severe skin injuries or defects. The company's core technology platform is the RECELL system, an automated and portable unit for producing cell therapy products from the patient's fresh tissue. Using this technology, the company can produce customized therapeutic products for a variety of applications, including burns, chronic wounds, and skin reconstruction. The second division of AVITA Medical's business model is the provision of wound care services. The company offers a wide range of services tailored to the needs of patients with severe skin injuries or defects. These services include surgical procedures, conservative wound care, and other measures to accelerate wound healing and improve skin regeneration. The third division of AVITA Medical's business model is the distribution of products and devices for medical applications. The company distributes a wide range of medical devices and accessories, including instruments for the application of the RECELL system and dermographs. In addition, customers can also access training and consulting services to ensure the proper use of the devices and products. Overall, AVITA Medical Inc is committed to improving the treatment of patients with serious skin injuries and defects, and to providing them with a better quality of life. The company has developed a wide range of products and services tailored to the needs of these patients. By utilizing the company's advanced technology platform, doctors and surgeons can produce customized therapeutic products specifically tailored to the needs of each individual patient, thereby reducing treatment duration and accelerating healing. AVITA Medical strives to continuously improve its products and services and develop new innovations to further enhance the treatment of patients with skin injuries and defects.

The expected revenue of AVITA Medical is 82.77 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of AVITA Medical is -32.01 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of AVITA Medical is currently -3.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AVITA Medical stock.

The price-to-sales ratio (P/S) of AVITA Medical is currently 1.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AVITA Medical stock.

The Eulerpool Quality Score for AVITA Medical is 3/10.

The ISIN of AVITA Medical is US05380C1027. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of AVITA Medical is A2P733. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of AVITA Medical is RCEL. The ticker symbol is used to trade AVITA Medical shares on the stock exchange.

AVITA Medical paid dividends every year for the past 0 years.

AVITA Medical is assigned to the 'Health' sector.

The dividends of AVITA Medical are distributed in USD.

All fundamentals and in-depth analysis of AVITA Medical

Our stock analysis for AVITA Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AVITA Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

AVITA Medical Stock
AVITA Medical Revenue→
AVITA Medical Stock
AVITA Medical Net Income→
AVITA Medical Stock
AVITA Medical P/E→
AVITA Medical Stock
AVITA Medical P/S→
AVITA Medical Stock
AVITA Medical EBIT→
AVITA Medical Stock
AVITA Medical Dividend→
AVITA Medical Stock
AVITA Medical Directors Dealings→
AVITA Medical Stock
AVITA Medical Stocks→
AVITA Medical Stock
AVITA Medical Market capitalization→
AVITA Medical Stock
AVITA Medical Debt→
AVITA Medical Stock
AVITA Medical Liabilities→
AVITA Medical Stock
AVITA Medical Equity→
AVITA Medical Stock
AVITA Medical AAQS→
AVITA Medical Stock
AVITA Medical Employees→
AVITA Medical Stock
AVITA Medical ROE→
AVITA Medical Stock
AVITA Medical ROA→
AVITA Medical Stock
AVITA Medical ROCE→
AVITA Medical Stock
AVITA Medical News→
AVITA Medical Stock
AVITA Medical Analyst Price Targets→

Health Stocks

AvitarAvitaAvricore HealthAvicannaAxe ComputeAvenue TherapeuticsAxim BiotechnologiesAvenir Wellness SolutionsAxoGenAvem Health PartnersAxsome TherapeuticsAvecho BiotechnologyAll Stocks A–Z →